|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Aastrom Biosciences Inc., of Ann Arbor, Mich., entered an alliance to jointly develop tissue regeneration treatments with the Musculoskeletal Transplant Foundation in Edison, N.J. The partners initially plan to combine Aastrom's Tissue Repair Cells (TRCs) with the foundation's allograft matrices for bone graft applications. They will share in the development and clinical trial expenses, and will adopt a coordinated promotion and marketing strategy for future products. In addition to allograft-based bone graft treatments, they plan to explore joint cartilage regeneration products and combinations of TRCs with the foundation's ceramic matrix technology. Aastrom's stock ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|